Dr. Edward Mills reports

LIR LIFE SCIENCES SIGNS DEVELOPMENT SERVICES AGREEMENT WITH OXYGEN HANDEL GMBH (OH) TO ADVANCE REGULATORY AND PRECLINICAL ROADMAP FOR TRANSDERMAL OBESITY PIPELINE

LIR Life Sciences Corp. has entered into a service agreement with Oxygen Handel GmbH, a specialized preclinical and regulatory development organization, to initiate phase 0 strategic development planning for the company's transdermal metabolic therapeutics pipeline.

Under the agreement, OH will conduct a Food and Drug Administration-focused regulatory and development road map designed to evaluate the optimal approval pathway for LIR's transdermal GLP-1- and GLP/GIP-based therapeutic candidates, including assessment of potential 505(b)(2) regulatory pathways, bridging strategies to existing approved molecules, formulation development requirements, and preclinical and clinical study sequencing. The engagement is intended to generate a comprehensive development plan, including study mapping, regulatory milestones, risk analysis and budget forecasting. The road map is further intended to establish a structured development framework for LIR's expanding transdermal pipeline, including current and future obesity and metabolic disease candidates.

LIR believes establishing a formalized translational and regulatory pathway at this stage has the potential to improve development efficiency, reduce execution risk and support more focused capital allocation as it advances its needle-free transdermal delivery platform.

"This agreement is an important operational milestone for us," said Edward Mills, chief executive officer of LIR Life Sciences. "As our pipeline continues to expand beyond individual molecules into a broader transdermal delivery platform, it becomes increasingly important to establish a clear and efficient regulatory and preclinical road map. We view this as the foundation for systematic advancement of multiple product candidates."

The initial phase 0 engagement is expected to include regulatory pathway analysis, product profile development, gap assessment for formulation and non-clinical requirements, and construction of a program-level development timeline to support future regulatory engagement and commercialization planning.

About LIR Life Sciences Corp.

LIR Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.

We seek Safe Harbor.